We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ...

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...

UBS lowered the firm’s price target on Teva (TEVA) to $27 from $30 and keeps a Buy rating on the shares. UBS says the pullback on the stock ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Teva Pharmaceutical Industries Ltd. (TEVA) has seen a decline of 13.92 percent in its stock value during Wednesday afternoon trading ...

BofA Securities made adjustments to its financial model for Teva Pharmaceutical Industries Ltd (NYSE:TEVA), resulting in a lowered price target. While the firm maintained a Buy rating on the stock, ...

Teva Pharmaceutical Industries swung to a fourth-quarter loss on lower revenue and an operating loss. Shares fell about 2.5% in premarket trading to $20.99.

Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...